Back
Pictures – Please see Figures 1-3.
There is a long overdue imperative to develop a robust, safe, and sustainable modality for ACF-HD.
We have described the successful design and development of this second generation HDFR with its enhanced new features that include increased resilience and longer running times, enhanced angle and speed consistency, improved ergonomics, solid state sensors for temperature and angle fidelity verifications, and a user-friendly App with Bluetooth Connectivity, to facilitate easy and convenience with monitoring and control of the HDFR. Developers and investors are needed to move this project to the bedside with animal and subsequently human clinical trials. There remains a clearly unmet imperative to develop ACF-HD in critically ill patients, in the peri-operative period, and in hospitalized patients, in general. There is also a place for the HDFR for the Home Hemodialysis patient.
We posit that our HDFR is the solution to meet this unmet need. Developers, investors, and sponsors are welcome.